Providing Answers, Support and Hope in Pennsylvania, Delaware and Southern New Jersey
The role of the CD6/ALCAM pathway and itolizumab in the treatment of patients with active lupus nephritis
Throughout this program you will learn more about:
- CD6/ALCAM pathway and its role in immuno-inflammation
- Contribution of the CD6/ALCAM pathway in the pathogenesis of SLE and lupus nephritis
- Mechanism of action of itolizumab and current clinical data in patients with SLE
- Design of the EQUALISE phase 1b clinical study in patients with active lupus nephritis
Meet the presenter:
Dr. Maple Fung is a board-certified nephrologist with a deep experience in developing drugs across all phases of development. She is currently the Head of Clinical Development at Equillium and began her career in academia as a faculty member and Assistant Professor at UCSD (University of California, San Diego) and the VA San Diego Healthcare System where she focused on genetic determinants of renal diseases and hypertension. During that time, Dr. Fung also led a number of investigator sponsored studies through grants from large pharmaceuticals companies. She then made her way to industry and has held clinical development and program leadership roles over the last decade at Amgen, Ardea Biosciences, Ionis Pharmaceuticals, and most recently Arena Pharmaceuticals. Her experience has spanned several therapeutic areas including nephrology, rheumatology, dermatology, and women’s health. Dr. Fung obtained an M.D. from the UCSD School of Medicine followed by training in Internal Medicine and Nephrology and continues to serve as a volunteer faculty in the renal division.